CoaguSense Overview
- Year Founded
-
2008
- Status
-
Acquired/Merged
- Employees
-
43
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$10M
- Investors
-
2
CoaguSense General Information
Description
Developer of a coagulation in-vitro diagnostics and monitoring system designed to offer point-of-care prothrombin time (PT) and international normalized ratio (INR) monitoring. The company's portable system uses clot detection technology that reduces the possibility of interference from blood constituents not involved in clot formation and offers rapid testing time, simplicity, and analytical results that correlate well with the leading methods of prothrombin time (PT) determination, providing physicians and patients with accurate and precise testing devices for determining prothrombin time.
Contact Information
Website
www.coag-sense.com(Operating Subsidiary)
Corporate Office
- 48389 Fremont Boulevard
- Suite 106
- Fremont, CA 94538
- United States
Corporate Office
- 48389 Fremont Boulevard
- Suite 106
- Fremont, CA 94538
- United States
CoaguSense Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series A) | 22-Oct-2021 | $10M | Completed | Generating Revenue | ||
| 2. Seed Round | 21-Nov-2016 | Completed | Generating Revenue | |||
| 1. Merger/Acquisition | 01-Jan-2016 | Completed | Generating Revenue |
CoaguSense Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
CoaguSense Patents
CoaguSense Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20030180824-A1 | The reaction chamber is coated with a dry coagulation initiator (throboplastin, kaolin or diatomaceous earth) and a timer that measures an interval of time between blood is received and the clot is formed in the reaction chamber | Active | 25-Mar-2002 | ||
| US-7235213-B2 | The reaction chamber is coated with a dry coagulation initiator (throboplastin, kaolin or diatomaceous earth) and a timer that measures an interval of time between blood is received and the clot is formed in the reaction chamber | Inactive | 25-Mar-2002 |
CoaguSense Signals
CoaguSense Acquisitions (1)
CoaguSense’s most recent deal was a Merger/Acquisition with DOASENSE. The deal was made on 22-Mar-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| DOASENSE | 22-Mar-2026 | Merger/Acquisition | Diagnostic Equipment |
CoaguSense FAQs
-
When was CoaguSense founded?
CoaguSense was founded in 2008.
-
Where is CoaguSense headquartered?
CoaguSense is headquartered in Fremont, CA.
-
What is the size of CoaguSense?
CoaguSense has 43 total employees.
-
What industry is CoaguSense in?
CoaguSense’s primary industry is Other Devices and Supplies.
-
Is CoaguSense a private or public company?
CoaguSense is a Private company.
-
What is the current valuation of CoaguSense?
The current valuation of CoaguSense is .
-
What is CoaguSense’s current revenue?
The current revenue for CoaguSense is .
-
How much funding has CoaguSense raised over time?
CoaguSense has raised $15M.
-
When was CoaguSense acquired?
CoaguSense was acquired on 22-Oct-2021.
-
Who acquired CoaguSense?
CoaguSense was acquired by i-SENS.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process